

Celestia S Higano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/147692/publications.pdf>

Version: 2024-02-01

74
papers

11,612
citations

159585

30
h-index

88630

70
g-index

75
all docs

75
docs citations

75
times ranked

12166
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	27.0	2,456
2	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	27.0	2,412
3	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	1.6	1,089
4	Quantitative and stoichiometric analysis of the microRNA content of exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14888-14893.	7.1	880
5	Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-L in advanced prostate cancer. <i>Cancer</i> , 2009, 115, 3670-3679.	4.1	756
6	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	30.7	572
7	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
8	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	1.6	448
9	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	7.0	273
10	Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. <i>Urology</i> , 2003, 61, 32-38.	1.0	228
11	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2008, 113, 975-984.	4.1	192
12	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. <i>Journal of Urology</i> , 2015, 194, 1537-1547.	0.4	179
13	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 509-521.	10.7	174
14	SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4698-4708.	7.0	137
15	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	1.9	91
16	Germline and Somatic Mutations in Prostate Cancer for the Clinician. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 515-521.	4.9	91
17	Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. <i>Urologic Clinics of North America</i> , 2004, 31, 331-352.	1.8	69
18	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2017, 18, 473-485.	10.7	67

#	ARTICLE	IF	CITATIONS
19	New and emerging agents for the treatment of castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 1-8.	1.6	54
20	Androgen Deprivation Therapy: Monitoring and Managing the Complications. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 909-923.	2.2	52
21	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer. <i>Prostate</i> , 2001, 47, 222-229.	2.3	51
22	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	4.1	49
23	A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. <i>Cancer Immunology Research</i> , 2014, 2, 988-999.	3.4	45
24	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. <i>Prostate</i> , 2016, 76, 810-822.	2.3	45
25	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	1.6	44
26	Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals. <i>JCO Oncology Practice</i> , 2022, 18, e697-e709.	2.9	44
27	Analysis and sorting of prostate cancer cell types by flow cytometry. , 1999, 40, 192-199.		43
28	Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-285.	1.6	42
29	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. <i>European Journal of Cancer</i> , 2019, 114, 107-116.	2.8	42
30	Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2015, 68, 795-801.	1.9	39
31	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	1.9	35
32	Chemotherapy-Induced Monoamine Oxidase Expression in Prostate Carcinoma Functions as a Cytoprotective Resistance Enzyme and Associates with Clinical Outcomes. <i>PLoS ONE</i> , 2014, 9, e104271.	2.5	30
33	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 469-481.	3.8	29
34	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 610-617.e3.	1.9	25
35	Potential use of custirsen to treat prostate cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 785.	2.0	22
36	Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?. <i>Nature Reviews Urology</i> , 2019, 16, 335-336.	3.8	22

#	ARTICLE	IF	CITATIONS
37	A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4746-4756.	7.0	22
38	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016, 76, 1303-1311.	2.3	21
39	Personalizing Androgen Suppression for Prostate Cancer Using Mathematical Modeling. <i>Scientific Reports</i> , 2018, 8, 2673.	3.3	21
40	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	3.9	20
41	Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 10-16.	1.9	16
42	Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis. <i>American Journal of Hematology</i> , 1987, 24, 93-99.	4.1	15
43	Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e9-81.e16.	1.6	15
44	Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy. <i>PLoS ONE</i> , 2015, 10, e0130372.	2.5	14
45	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	7.0	12
46	Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1531.	7.1	11
47	Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management. <i>Journal of Urology</i> , 2018, 200, 319-326.	0.4	11
48	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. <i>Journal of Clinical Oncology</i> , 2012, 30, 25-25.	1.6	11
49	ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). <i>Journal of Clinical Oncology</i> , 2013, 31, 7-7.	1.6	11
50	Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE 025 monoclonal antibody. <i>World Journal of Surgery</i> , 1991, 15, 122-127.	1.6	10
51	New treatment options for patients with metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 340-345.	7.7	10
52	Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin. <i>Cancer</i> , 2008, 112, 2181-2187.	4.1	9
53	Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. <i>Canadian Urological Association Journal</i> , 2014, 8, 789.	0.6	9
54	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e191-e198.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy. <i>American Journal of Clinical Pathology</i> , 2022, 158, 270-276.	0.7	7
56	The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 1184-1186.	0.4	5
57	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 363-365.	3.9	5
58	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	3.9	5
59	Pearls to Pivoting a Multidisciplinary Prostate Cancer Survivorship Program During the COVID-19 Pandemic. <i>European Urology Oncology</i> , 2020, 3, 397-399.	5.4	4
60	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	2.4	4
61	A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2754-2761.	1.3	3
62	Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 711-720.	2.2	3
63	Sexual rehabilitation recommendations for prostate cancer survivors and their partners from a biopsychosocial Prostate Cancer Supportive Care Program. <i>Supportive Care in Cancer</i> , 2022, 30, 1853-1861.	2.2	3
64	Does nonmetastatic castration-resistant prostate cancer still exist?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 350-351.	27.6	2
65	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 32-32.	1.6	2
66	Back to Basics: Addressing Bone Health in Men with Prostate Cancer on Androgen Deprivation Therapy. <i>European Urology Oncology</i> , 2019, 2, 562-564.	5.4	1
67	A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 209-209.	1.6	1
68	Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 74-74.	1.6	1
69	Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 148-148.	1.6	1
70	Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED.. <i>Journal of Clinical Oncology</i> , 2013, 31, 30-30.	1.6	1
71	Mapping the course after CHARTED. <i>Nature Reviews Urology</i> , 2015, 12, 656-658.	3.8	0
72	Introduction to the seminar series: Optimal management during ADT to mitigate complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 44.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020, 126, 2935-2937.	4.1	0
74	Real-world experience with sipuleucel-T in patients (pts) ≥80 years old with metastatic castration-resistant prostate cancer (mCRPC): Data from PROCEED. <i>Journal of Clinical Oncology</i> , 2013, 31, 131-131.	1.6	0